Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | METAP2 | P50579 | 3/20 | 0.40 |
| ▸ | METAP1 | P53582 | 3/20 | 0.40 |
| ▸ | XDH | P47989 | 2/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7561710 | 1.00 | FAAH (0.42) | FAAHCES1DAGLANPC1SMN1; SMN2 | |
| SCHEMBL5431040 | 1.00 | FAAH (0.42) | FAAHCES1DAGLANPC1SMN1; SMN2 | |
| SCHEMBL7732346 | 1.00 | FAAH (0.42) | FAAHCES1DAGLANPC1SMN1; SMN2 | |
| SCHEMBL8059666 | 0.86 | HDAC3 (0.42) | FAAHCES1DAGLANPC1SMN1; SMN2 | |
| SCHEMBL8136679 | 0.86 | HDAC3 (0.42) | FAAHCES1DAGLANPC1SMN1; SMN2 | |
| SCHEMBL7732480 | 0.85 | HSD17B10 (0.41) | DAGLANPC1SMN1; SMN2MAPTRAB9A | |
| SCHEMBL7736136 | 0.85 | XDH (0.46) | NPC1SMN1; SMN2MAPTRAB9ATP53 | |
| SCHEMBL7858147 | 0.85 | XDH (0.46) | NPC1SMN1; SMN2MAPTRAB9ATP53 | |
| Hydrochloric Acid SCHEMBL6349192 | 0.85 | HDAC3 (0.41) | FAAHCES1DAGLANPC1SMN1; SMN2 | |
| SCHEMBL7729637 | 0.84 | METAP2 (0.41) | NPC1SMN1; SMN2MAPTRAB9ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-01 | — | — | US | disclosed |
| EP-1516877-A1 | Amine derivatives as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2004-07-22 | — | — | US | disclosed |
| EP-1397340-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-03-17 | — | — | EP | disclosed |
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
| WO-2002098850-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-12-12 | — | — | WO | disclosed |
| EP-1161422-A1 | AMINE DERIVATIVES AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-12-12 | — | — | EP | disclosed |
| WO-2000055144-A1 | AMINE DERIVATIVES AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | FAAH 602/4885CES1 154/4885DAGLA 1772/4885 |
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | FAAH 479/4885CES1 272/4885DAGLA 2304/4885 |
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | FAAH 602/4885CES1 154/4885DAGLA 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.